Tag: Patients
Search News
Blood Cancer Awareness Month 2019
1st September 2019
Today marks the start of Blood Cancer Awareness Month. Our researchers are committed to work to understand the biology of blood cancer and harness this knowledge to identify new treatment strategies to help those affected.
Read more
Understanding familial leukaemia
8th August 2019
In 2014, the charity Bloodwise awarded a 5-year programme grant to a team from Queen Mary University of London to support research to better understand the nature of the faulty genes responsible for an inherited/familial predisposition to MDS/AML.
Read more
2019 ASCO Annual Meeting
4th June 2019
Professor Peter Schmid, Lead of the Centre for Experimental Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London, attended this year’s ASCO Annual Meeting and today presented updated survival data from the IMpassion130 trial.
Read more
AR alterations in prostate cancer
16th May 2019
Recent findings from a study published in JAMA Oncology have identified genetic markers within blood samples which may indicate whether patients with prostate cancer will respond to hormonal therapies. The study may represent an important step forward for the development of more personalised treatments for advanced prostate cancer.
Read more
IBD and bowel cancer
29th April 2019
April is Bowel Cancer Awareness Month. We recently spoke with Dr Kit Curtius about her work which focuses on understanding how normal tissues evolve to become cancerous, with a particular interest in gastrointestinal pre-malignancies such as inflammatory bowel disease.
Read more
Therapy for high-grade glioma
2nd April 2019
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.
Read more